This document discusses pharmacoeconomics and provides definitions, principles, perspectives, types of costs and consequences, and methods of pharmacoeconomic evaluation. Pharmacoeconomics analyzes the costs and benefits of drug therapies to health systems and society. It considers costs from multiple perspectives including patients, providers, payers, and society. Costs include direct medical, direct non-medical, and indirect costs. Consequences include clinical, economic, and humanistic outcomes. Common methods of pharmacoeconomic evaluation are cost-of-illness analysis, cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, and cost-utility analysis. These methods are used to inform healthcare decisions at both the individual patient
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another.
By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Statistical softwares used in pharmacoeconomics @ RxVichuZ!! :)RxVichuZ
This summarized outline deals with SOFTWARES USED IN PHARMACOECONOMIC STUDIES, their precise details, merits & summarized relevant applications.
With respect to PHARMACOEPIDEMIOLOGY & PHARMACOECONOMICS subject.
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
In this presentation i have tried to explain in detail about the measurements of the outcomes which are used in epidemiology such as prevalence, incidence, fatality rate, crude death rate etc.
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another.
By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
Statistical softwares used in pharmacoeconomics @ RxVichuZ!! :)RxVichuZ
This summarized outline deals with SOFTWARES USED IN PHARMACOECONOMIC STUDIES, their precise details, merits & summarized relevant applications.
With respect to PHARMACOEPIDEMIOLOGY & PHARMACOECONOMICS subject.
Pharmacological Approach to Drug DiscoverySuhas Reddy C
For better understanding of students. This will give you a detailed explanation of Pharmacological approach. Contact me through comment section if you need any assistance in understating
In this presentation i have tried to explain in detail about the measurements of the outcomes which are used in epidemiology such as prevalence, incidence, fatality rate, crude death rate etc.
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
There is often more than one way of doing something in healthcare.
For
example, there may be two different drugs that can be used to treat
depres sion, or two surgical techniques for the management of dysmenorrhoea.
Note that interventions may be compared against each other ( for example
antibiotic A against antibiotic B) or against a ' do nothing' scenario.
There are different ways in which we can choose one of these options.
We may
decide to pick the more effective surgical technique, or we may decide to
select the less costly antidepressant. Economic evalu ation is a generic term for
techniques that are used to identify, measure and value both the costs and the
outcomes of healthcare interventions. An economic evaluation is concerned
with identifying the differences in costs and outcomes between options. It can
be defined as a study that compares the costs and benefits of two or more
alternative interventions; so, the main components are costs and benefits
Health economics is a branch of economics concerned with issues related to efficiency, effectiveness, value and behavior in the production and consumption of health and healthcare.
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...home
Whereas the number and quality of economic evaluations of CAM have increased in
recent years and more CAM therapies have been shown to be of good value, the majority of CAM
therapies still remain to be evaluated
Biostatics and Research Methodology are essential components of the field of Pharmacy related research. They involve the application of statistical techniques and research methodologies to analyze and interpret data in biological, medical, and public health studies. This subject is applicable to B. Pharm as well as M. pharm students
Regulatory Requirements For New Drug Approval.
This topic is from Industrial Pharmacy-II, B.Pharm Final year VIIth semester.
It include rule and regulations related to new drug approval for clinical use.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
3. Input costs Output costs
Healthcare
What is pharmacoeconomics?
3 8/11/2019
4. Pharmacoeconomics has been defined as the description and analysis of the
cost of drug therapy to healthcare system and society.
pharmacoeconomics
Pharmakon-
drug
Oikonomia-
management of
houselod
Oikas-house
Nomas-law
Definition
4 8/11/2019
5. Outcome research .
Means to
Identify,measure,evaluate the result of health care researches in general.
Cost.
It is the value of resources consumed by a program or drug therapy of interest.
Consequences.
Effects, outputs or outcomes of program or drug therapy of interest.
Outcome
research
cost consequences
Principle
5 8/11/2019
8. Assessing costs and consequences:
1.Patient perspectives.
Acccording to patient
E.G Insurance copayments, Indirect costs, Drug costs
2.Provider perspectives.
Provider can be hospitals, managed-care organization.
3.Payer perspectives.
Direct cost
E.G insurance company ,employers or the Government.
4.Social perspectives.
Broadest
Considers benefits of society
Include morbidity and mortality
Perspectives
8 8/11/2019
10. The value of resources consumed by a program or drug therapy,of interest, is
defined as cost.
Health care costs are categorized as..
1.Direct medical costs.
Drugs and equipment, medical supplies ,Laboratory and Diagnostic
tests,Hospitilizations,and Physician visits.
Direct medical costs can be subdivided into
Fixed and variable.
10
Costs
8/11/2019
11. 2.Direct nonmedical costs.
That are result of illness or disease but do not involve purchasing
medical services.
Transportation to and from health care facilities, Extra trips to the
emergency department, child or family care expenses, special diets etc.
3.Indirect nonmedical cost.
Morbidity cost –loss of reproductivity (missing work)+Mortality cost -Loss
of years of service due to premature death.
Two techniques are used to estimate indirect cost
1.Human capital(HC)
2.Willingness to pay(WTP) methods.
11 8/11/2019
12. 4.Intangible costs :
Nonfinancial outcomes of disease and medical care such as pain, suffering,
inconvenience and grief.
5.Opportunity costs:
Economic benefits forgone when using one therapy instead of the next best
alternative therapy.
Value of alternative forgone
6.Incremental costs.
The extra cost required to purchase an additional units of effects
12 8/11/2019
14. Consequences (Outcomes):
Is defined as the effects ,outputs ,or outcomes of the program or drug therapy
of interest.
Consequences are categorized as.
Economic outcomes:
Comparing direct ,indirect, intangible costs with the consequences of medical
treatment alternatives.
Clinical outcomes:
Medical events occur as a result of disease or treatment (e.g. safety and efficacy
end point).
Humanistic outcomes:
Consequences of disease or treatment on patient functional status such as
physical function, social function ,general health and well-being and life
satisfaction.
14 8/11/2019
15. Positive outcomes -Desired effects of a drug.
Negative outcomes -ADR or toxicity of a drug.
Intermediate outcome- Can serve as a proxy for more relevant final outcome
15 8/11/2019
16. Methods of pharmacoeconomics evaluation
1.Cost of
illness
2.Cost
minimiza
tion
3.Cost
benefit
4.Cost
effective
ness
5.Cost
utility
16 8/11/2019
17. Cost of illness (COI)Evaluation
COI identifies and estimates the overall costs of a particular disease for a defined
population.
COI evaluation also known as burden of illness.
It involves measuring the direct and indirect costs attributable to a specific
disease Such as diabetes ,mental disorder, or cancer
COI Evaluation is not used to compare competing treatment alternatives but to
provide an estimation of the financial burden of a disease.
17 8/11/2019
18. Cost Minimization analysis
Cost minimization analysis involves the determination of the least costly
alternative. When comparing two or more treatment alternatives .
With CMA the two alternatives must be equivalent therapeutically .
For e.g.
If a drug A and B are antiulcer agents equivalent in efficacy and adverse drug
reaction ,then the costs of using these drugs could be compared using CMA.
18 8/11/2019
19. Cost benefit Analysis
Cost benefit analysis is a method that allows for identification ,measurement
and comparison of the benefits and costs of a program or treatment alternative.
Both the costs and the benefits are measured and converted into equivalent
dollars .
These costs and benefits are expressed as a ratio(a benefit to cost ratio)
Many CBAs measure and quantify direct costs and direct benefits only due to
difficulties in measuring indirect and intangible benefits.
This approach is widely used in health economics.
19 8/11/2019
20. Cost effectiveness analysis
CEA is a way of summarizing the health benefits and resources used by
competing healthcare program so that policymakers can choose among them.
It measures effectiveness(health benefits) in natural units(e.g years of life saved
,disease healed ) and the cost in money.
It compares therapies with qualitatively similar outcomes in a particular
therapeutics area. for instances, in severe reflux oesophagitis,using a proton
pump inhibitor compared to using H2 blockers .
20 8/11/2019
21. The results of CEA are expressed as a ratio either as an average cost-
effectiveness Ratio (ACER)or as an incremental cost effectiveness ratio(ICER)
1.ACER= health care costs/clinical outcome
This allows the cost and outcomes to be reduced to a single value to allow for
comparison.
2.ICER=Difference in cost (A-B)/Difference in benefits(A-B)
This formula yields the additional cost required to obtain the additional effect
gained by switching from drug A to drug B.
21 8/11/2019
22. Cost utility Analysis
CUA is the most appropriate method to use when comparing programs and
treatment alternatives that are life extending with serious side effects (e.g. cancer
chemotherapy ),those whose produce reduction in morbidity rather than mortality
(e .g , medical treatment arthritis),
and when HRQOL (Health related quality of life) is the most important health
outcome being examined.
CUA can compare cost,quality,and quantity of patients years.
22 8/11/2019
23. Methods Description Applications
COI
Estimates cost of a disease
on define population
Use to provide baseline to
compare prevention/treatment
options against.
CMA
Finds the least expensive
cost alternative
Use when benefits are the same
CBA
Measures benefits in
monetary units and
computes a net gain
Can compare programs with
different objectives
CEA
Compares alternatives with
therapeutics effects
measured in physical units
Can compare drugs /programs
that differ in clinical outcomes
and use the same unit of benefits
CUA
Compares consequences in
utility units rather than
physical units
Use to compares drug /programs
that are life extending with
serious side effects
23 8/11/2019
24. Applications
In decision making
regarding drug therapy
Selecting cost effective
drug for an
organizational
formulary
Supports clinical
decisions ,ranging from
the level of patient to
entire healthcare
system
24 8/11/2019